HEALTHJun 5 · 13:59 UTCTHE HILLNathaniel Weixel

FDA reviewing safety of abortion drug mifepristone

The FDA is conducting a safety review of the abortion drug mifepristone. This action could lead to restrictions on its use and distribution, supported by anti-abortion groups as a potential victory for their cause.

Nexus surfaces and summarizes. The full story lives at the source.

Mentioned

FDAorganizationmifepristonetopicanti-abortion groupsorganizationTrump administrationorganizationretrospective analysistopic

Spot something wrong with this article?Report a problem →

Forward this

Related Signal

Adjacent reporting

HEALTHJun 5 · 04:55 UTC
FDA launches safety study for abortion pill mifepristone, source says
HEALTHApr 14 · 14:28 UTC
Hawley urges DOJ probe into abortion pill maker over safety concerns
HEALTHJun 5 · 13:17 UTC
STAT+: Pharmalittle: We’re reading about Roche accusing U.S. of ‘blackmail,’ a ruling on skinny labels, and more
HEALTHMay 8 · 15:23 UTC
Former FDA leaders, pharma speak out on mifepristone
HEALTHMay 14 · 22:24 UTC
Supreme Court preserves broad access to abortion drug mifepristone
HEALTHMay 5 · 21:05 UTC
Telehealth Abortion Is Still Possible Without Mifepristone